Johnson & Johnson’s (J&J’s) proposed 340B rebate model, which has not received government approval, would give the drugmaker significantly more [...] …
Category: Regulatory
Drugmaker Kedrion Biopharma has posted a refund notice to 340B providers, and Mylan notified covered entities of National Drug Code [...] …
The federal agency that oversees the 340B program did not approve drugmaker Johnson & Johnson’s (J&J’s) proposal to convert certain [...] …
In a move that would fundamentally alter the 340B program, pharmaceutical giant Johnson & Johnson (J&J) told hospitals this morning [...] …
French drugmaker Sanofi has reportedly asked some hospitals for data relating to 340B purchases of a popular drug used to [...] …
Six national hospital associations recently urged the Supreme Court to correct what they called the Department of Health and Human [...] …
A federal court last week sided with a group of Texas hospitals’ efforts to block—at least temporarily—a Department of Health [...] …
A major hospital advocacy group recently urged congressional advisers to “carefully consider” the potential negative consequences of any new efforts [...] …
A former Pfizer executive and current biopharmaceutical consultant took aim this week at what she called the “poorly managed” 340B [...] …
The Health Resources and Services Administration (HRSA) has requested public comment on how petitioners file their initial claims in the [...] …